This page contains a Flash digital edition of a book.
Flow Cytometry


A Step 1: Remove noise


B Step 2: Well identification


Figure 4: Automated high throughput flow cytometer. A BD Accuri C6 flow cytometer is integrated to an IntelliCyt HyperCyt sampler which in turn is integrated with a Beckman Coulter NX. Plates are positioned directly on to the HyperCyt using a plate shuttle


D Step 4: Export and analyse data


C Step 3: Identify cell populations


Figure 5: HyperCyt method for high throughput flow cytometry. The illustrated assay assesses the ability of test compounds to inhibit the upregulation of CD11b in GRO- stimulated neutrophils in whole human blood. 10ul volumes of whole blood is first treated with compound and stimulated with GRO for a further 15min before surface maker labelling, RBC cell lysis and fixation using 4% PFA. Samples are aspirated from microplate wells and delivered to a BD-Accuri C6 flow cytometer as a series of fluid volumes (~2ul each) separated by air bubbles. A four-second flush step was introduced at the end of each row of wells. The samples are detected in the flow cytometer as discrete clusters of events that appear at uniform time intervals. Each cluster represents ~2,000 cells sampled from a well. Data is then processed by IntelliCyt’s Hyperview software. A: The first step in processing the data is to remove ‘noise’ associated with bubbles. B: The second step is to associate each time separated cell cluster with its corresponding wells – well identification. In this case 96 separate peaks can be identified. The larger time interval every 12 wells corresponds to a four-second plate shake and probe flush step introduced into the sampling process. C: The third stage involves typical flow cytometry data analysis where the populations of interest are identified and appropriate gating strategy applied. D: Finally, data is exported and automatically analysed using Activity Base XE (IBDS, Guildford, UK). Graphs depict the inhibition of GRO stimulated CD11b upregulation using the CXCR2 antagonist SCH52712318


Drug Discovery World Spring 2013


47


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80